Obesity diminishes response to PD-1-based immunotherapies in renal cancer

BACKGROUND: Obesity is a major risk factor for renal cancer, yet our understanding of its effects on antitumor immunity and immunotherapy outcomes remains incomplete. Deciphering these associations is critical, given the growing clinical use of immune checkpoint inhibitors for metastatic disease and...

Full description

Saved in:
Bibliographic Details
Published in:J Immunother Cancer
Main Authors: Boi, Shannon K, Orlandella, Rachael M, Gibson, Justin Tyler, Turbitt, William James, Wald, Gal, Thomas, Lewis, Buchta Rosean, Claire, Norris, Katlyn E, Bing, Megan, Bertrand, Laura, Gross, Brett P, Makkouk, Amani, Starenki, Dmytro, Farag, Kristine I, Sorge, Robert E, Brown, James A, Gordetsky, Jennifer, Yasin, Hesham, Garje, Rohan, Nandagopal, Lakshminarayanan, Weiner, George J, Lubaroff, David M, Arend, Rebecca C, Li, Peng, Zakharia, Yousef, Yang, Eddy, Salem, Aliasger K, Nepple, Kenneth, Marquez-Lago, Tatiana T, Norian, Lyse A
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2020
Subjects:
Clinical/Translational Cancer Immunotherapy
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7757487/
https://ncbi.nlm.nih.gov/pubmed/33427691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000725
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items